· Published by Health Canada · Official notice
Notice about Health Canada advisories
May 2006
Subject: Attention Deficit Hyperactivity Disorder (ADHD) Drugs: Updated and Standardized Labelling Regarding Very Rare Cardiac-Related Adverse Events
Dear Health Care Professional,
Health Canada wishes to inform you that the prescribing information of all drugs indicated for the treatment of ADHD in adults and children, has been updated to include standardized cautionary prescribing information identifying risk factors for cardiac-related adverse events with this class of drugs, and to provide recommendations to reduce these risks. The changes affect the Contraindications, Warnings and Precautions, Dosing recommendations, and Information for the Patient.
| Brand Name | Manufacturer |
|---|---|
| ® Trademark used under licence to Janssen-Ortho Inc. | |
| ADDERALL XR® (mixed salts amphetamine extended-release) | Shire BioChem Inc. |
| ATTENADE™ (dextromethylphenidate) |
Bioavail Pharmaceuticals Canada [approved, but the manufacturer has not marketed in Canada] |
| BIPHENTIN® (methylphenidate controlled release) |
Purdue Pharma [approved, but the manufacturer has not marketed in Canada] |
| CONCERTA® (methylphenidate extended release) | Janssen-Ortho Inc. |
| DEXEDRINE® (dextroamphetamine) | GlaxoSmithKline Inc. |
| RITALIN® (methylphenidate) | Novartis Pharmaceuticals Canada Inc. |
| RITALIN SR® (methylphenidate extended release) | Novartis Pharmaceuticals Canada Inc. |
| STRATTERA® (atomoxetine) | Eli Lilly Canada Inc. |
Cardiovascular Adverse Events Associated with ADHD Drugs:
Theoretically there exists a pharmacological potential for all ADHD drugs to increase the risk of sudden/cardiac death. All medications for the treatment of ADHD are sympathomimetic. The stimulatory effects from these drugs on the sympathetic nervous system are usually mild or moderate, but in patients of all ages, particularly those with cardiovascular compromise, these effects may result in serious adverse events including sudden/cardiac death. Reports of these serious adverse events are very rare.
In patients treated with ADHD drugs, neither clinical studies nor post-marketing reports have shown to date that the incidence or reporting rates of serious cardiac adverse events, including fatalities, are greater than background rates. Additionally, there is no evidence to show that, in terms of cardiac risk, any one of the drugs indicated for the management of ADHD is better or worse than the others. There is ongoing international discussion about the best way to design clinical studies to further investigate these issues.
Additional information on ADHD Drugs and Cardiac Adverse Events
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any serious or unexpected adverse reactions in patients receiving any ADHD drug should be reported to Health Canada at the following addresses:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Bureau of Cardiology, Allergy and Neurological Sciences (BCANS)
E-mail: BCANS_Enquiries@hc-sc.gc.ca
Tel: (613) 941-1499
Fax: (613) 941-1668
Your professional commitment in this regard is important to protecting the well-being of your patients by contributing to early signal detection and informed drug use.